Once-daily tobramycin in the treatment of adult patients with cystic fibrosis

European Respiratory Journal

Volumn 19, Issue 2, 2002, Pages 303-309

  Whitehead, A ^a   Conway, S P ^a   Etherington, C ^a   Caldwell, N A ^a   Setchfield, N ^a   Bogle, S ^a  

^a SEACROFT HOSPITAL   (United Kingdom)

Author keywords

Aminoglycosides; Cystic fibrosis; Tobramycin

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; GENTAMICIN; IMIPENEM; MAGNESIUM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POTASSIUM; TOBRAMYCIN;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HEARING; HUMAN; KIDNEY FUNCTION; LUNG FIBROSIS; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; OTOTOXICITY; POTASSIUM BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; RESPIRATORY TRACT DISEASE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; FORCED EXPIRATORY VOLUME; HUMANS; LACTAMS; MAXIMAL MIDEXPIRATORY FLOW RATE; MIDDLE AGED; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TOBRAMYCIN; VITAL CAPACITY;

EID: 0036177022     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00221602     Document Type: Article

References (32)

1. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides
2. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess
3. Once daily dosing decreases renal accumulation of gentamicin and netilmicin
4. Single or multiple daily doses of aminoglycosides: A meta-analysis
5. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis
6. Pharmacokinetics of antimicrobial drugs in cystic fibrosis: Aminoglycoside antibiotics
7. Antibiotic use in cystic fibrosis
8. Once v. thrice daily gentamicin in patients with serious infections
9. The chest radiograph in cystic fibrosis: A new scoring system compared with the Chrispin-Norman and Brasfield scores
10. Long-term study of 105 patients with cystic fibrosis: Studies made over a 5 to 14 year period
11. Intensive treatment of a pseudomonas chest infection in cystic fibrosis: A comparison of tobramycin and ticarcillin, and netilmycin
12. Aminoglycosides
13. Aminoglycosides once daily?
14. Kinetic model for gentamicin dosing with the use of individual patient parameters
15. Pharmacokinetics of dosing regimens which utilise multiple intravenous infusions: Gentamicin in burn patients
16. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis
17. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis
18. Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis
19. Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients
20. Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in three doses in cystic fibrosis
21. Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients
22. Once-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin
23. Evaluation of a once-daily netilmicin regimen in the treatment of cystic fibrosis
24. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients
25. Risk factors for the development of auditory toxicity in patients receiving antibiotics
26. Cystic fibrosis: Antibiotic prescribing practices in the United Kingdom and Eire
27. Home v hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis
28. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis
29. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients
30. Pharmacokinetics of tobramycin in cystic fibrosis
31. The post antibiotic effect
32. Postantibiotic effects